J&J International Baby, Beauty Lines Could Lead Trimming 10% Of Consumer Portfolio
J&J plans to cut 10% of its consumer health portfolio, with most divestitures in the baby and beauty care segments outside the US. It plans to focus on growing “stronghold” categories of skin health and self care, including Aveeno and Tylenol.
You may also be interested in...
The iconic talc-based product will no longer be available for purchase in the US and Canada after supplies run out. Standing firm on the safety of Johnson’s Baby Powder, J&J attributes the move to declining demand due to changing consumer habits, misinformation “and a constant barrage of litigation advertising.”
J&J is prioritizing Tylenol production on caplets easiest to manufacture to maximize output as it manufactures the line around the clock, says CEO Alex Gorsky. First-quarter US OTC sales soared 35% as consumers stockpiled due to COVID-19, though the pandemic led J&J to downgrade its 2020 outlook.
Recommendations from an FDA-led interagency work group regarding methods for detecting and measuring asbestos in talc and talc-containing cosmetics will be presented at the agency’s planned public meeting in Silver Spring, MD, on 4 February. The recommendations are summarized in the FDA's meeting notice, which follows contentious cosmetic product recalls based on asbestos findings.